Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 8,374 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 4 Interventional Results available

Study of Metoclopramide in Small Bowel Capsule Endoscopy

NCT01630109
View directory record Official record
Conditions
Pill Capsule Endoscopy Completion Rates
Interventions
Metoclopramide, Placebo
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

NCT06334419
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Gaboxadol, Placebo
Drug
Lead sponsor
Craig Erickson
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT00775528
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
1 Month to 6 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

NCT01288911
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
enzalutamide, bicalutamide
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
36
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 22, 2026, 12:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

NCT00748371
View directory record Official record
Conditions
Platelet Aggregation
Interventions
aspirin, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional

A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

NCT06259981
View directory record Official record
Conditions
Obesity
Interventions
GLY-200, Placebo
Drug
Lead sponsor
Glyscend, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Clearwater, Florida • Ocoee, Florida • Marrero, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions
SAGE-718, SAGE-718-matching Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

NCT03892499
View directory record Official record
Conditions
Healthy
Interventions
Olinciguat, Itraconazole
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-05175157 In Healthy Volunteers

NCT01274663
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 22, 2026, 12:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Search to Advance Limited Use of Opioids Pilot: Optimization of Non-Opioid Therapy With a Steroid

NCT06074263
View directory record Official record
Conditions
Pain Management
Interventions
Dexamethasone 8mg, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 22, 2026, 12:59 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Tofacitinib, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
64
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

NCT01472081
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Pazopanib, Sunitinib, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
10
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Human Lung Responses to Respiratory Pathogens

NCT01967628
View directory record Official record
Conditions
Respiratory Infection
Interventions
Vitamin D3 (cholecalciferol), Placebo Sugar Pill
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 4 Interventional Results available

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

NCT04434664
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Hypertension
Interventions
Amlodipine Besylate, Metoprolol Succinate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Xanamem™, Placebo (for Xanamem™)
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 12:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy-Induced Immune Modulation: Part III

NCT03643744
View directory record Official record
Conditions
Actinic Keratosis, Photodynamic Therapy
Interventions
Celecoxib 200mg, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

NCT01381887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 22, 2026, 12:59 AM EDT
Withdrawn Phase 1 Interventional

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

NCT04280471
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease, Severe Gastrointestinal Tract Acute Graft Versus Host Disease, Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
Interventions
Fecal Microbiota Transplantation Capsule
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 3 Interventional

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799
View directory record Official record
Conditions
Traumatic Brain Injury, Memory Deficits
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 2 Interventional

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

NCT03198793
View directory record Official record
Conditions
Hypertension
Interventions
QGC001
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 22, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

NCT00693121
View directory record Official record
Conditions
Traumatic Brain Injury, Posttraumatic Confusional State, Delirium
Interventions
Amantadine hydrochloride, Placebo capsule
Drug
Lead sponsor
Methodist Rehabilitation Center
Other
Eligibility
16 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 22, 2026, 12:59 AM EDT